Study to learn if 200mg test drug (Fostamatinib) helps people with Large B-Cell Lymphoma,a type of blood cancer - Not applicable

Study identifier:D4302C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)

Medical condition

Diffuse Large B-Cell Lymphoma

Phase

Phase 2

Healthy volunteers

No

Study drug

Fostamatinib

Sex

All

Actual Enrollment

101

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Dec 2011
Primary Completion Date: 01 Oct 2013
Study Completion Date: 01 Oct 2013

Study design

Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria